|This article relies on references to primary sources. (September 2013)|
||This article contains wording that promotes the subject in a subjective manner without imparting real information. (September 2013)|
||A major contributor to this article appears to have a close connection with its subject. (September 2013)|
April 28, 1963 |
|Fields||Medicinal chemistry, green chemistry, drug discovery|
|Institutions||Central Drug Research Institute|
|Alma mater||Lucknow University|
Atul Kumar [अतुल कुमार्] (Born, April 28, 1963, Lucknow, India) is a scientist in the Central Drug Research Institute (CDRI) of Lucknow, India. His areas of research are organic chemistry, medicinal chemistry and drug design. He has made significant contributions to research on osteoporosis, cancer, Tuberculosis, diabetes and Stem cell. He also has considerable contributions in the area of organic chemistry particularly in the development of organocatalysed synthesis, Biomimetic synthesis, multicomponent reaction, Green chemistry, sonochemistry, enzymatic synthesis, and diversity oriented synthesis, Functional Ionic Liquid Mediated Synthesis (FILMS).
Education and profession
Atul Kumar obtained his masters degree and Ph.D from Lucknow University, then worked as a post-doc at the SUNY Buffalo. He is working as a Senior Principal scientist (Deputy Director) in the department of Medicinal Chemistry at the Central Drug Research Institute in Lucknow, India. He has developed a new drug candidate "CENTHANK" CDRI-99-373,(anti-resorptive agent)for the treatment of osteoporosis which is currently in Phase I clinical trials, diabetes and breast cancer, which are in preclinical stages. Dr. Kumar has many awards in his credit such as Organization of Pharmaceutical Producers of India (OPPI) OPPI SCIENTIST AWARD-2007, award is given by,Hon. Minster for Chemical and Fertilizers, Government of India at Mumbai In the area of medicinal chemistry, he has developed a natural product inspired diversity oriented synthesis of tetrahydroquinoline analogues as antitubercular agents, he has reported pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents, design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents. He has reported a Novel diastereoselective synthesis of spiropyrrolidine-oxindole derivatives as anti-breast cancer agents
In the area of organic synthesis, he has been involved in the development of new catalysts such as Liposomised mCPBA (LIP-mCPBA), new solid-supported hypervalent iodine reagents, and the use of human hemoglobin (HbA) and supramolecular carbohydrate molecules as solid catalysts for the synthesis of bioactive molecules. He has extensively contributed to the development of organocatalysed synthesis, biomimetic synthesis, multicomponent reaction, sonochemistry, enzymatic synthesis, high-throughput synthesis and diversity oriented synthesis.
Kumar was the first to demonstrate that single nucleotides have the ability to catalyze organic reactions, and performed biomimetic reductive amination, which is considered as one of the most genuine biomimetric reactions of organic chemistry. This single-nucleotide catalysis has immense impact on many fields of science such as chemistry, biochemistry, and prebiotic studies, especially the RNA world and DNA world hypothesis for understanding the origin of life on Earth.
Kumar has reported an efficient and conceptually different approach toward C-H bond activation by using iodine mediated sp3 C-H functionalization for the synthesis of alkyl azarene pyridinium zwitterions.
Kumar has recently demonstrated a new protocol for organic synthesis involving functional ionic liquids and named this new methodology as Functional Ionic Liquid Mediated Synthesis (FILMS). Dr kumar has reported Nanoparticle catalyzed reaction (NPCR)Ugi-reaction in aqueous medium
These studies have resulted in publication of about 75 original research papers, and 42 patents.
- "Biodata of Dr. Atul Kumar". Archived from the original on 18 September 2010. Retrieved 15 September 2010.
- Template:Cite Patent US Patent no7582653 and AU2033288644. web, http://www.indianexpress.com/news/cdri-develops-molecule-to-tackle-osteoporosis/528361/2, http://www.cdriindia.org/safety-clinical2.htm
- CDRI (2004). "Annual Report 2003-2004".
- "Natural Product Inspired Diversity Oriented Synthesis of Tetrahydroquinoline Scaffolds as Antitubercular Agent". Retrieved 1 July 2013.
- "Bioorganic & Medicinal Chemistry Letters" (pdf). Retrieved 1 July 2013.
- Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agent
- http://pubs.rsc.org/en/content/articlelanding/2013/ra/c3ra21595d#!divAbstract. Missing or empty
- Kumar, Atul; Siddharth Sharma, Ram Awatar Maurya (2010), "Single Nucleotide-Catalyzed Biomimetic Reductive Amination", Advanced Synthesis and Catalyst 352 (13): 2227–2232, doi:10.1002/adsc.201000178.
- Kumar, Atul; Garma Gupta, Sumen Srivastava, (2011), "Synthesis of New Class of Alkyl Azarene Pyridinium Zwitterions via Iodine Mediated sp3 C–H Bond Activation", Organic Letters 13 (24): 6366, doi:10.1021/ol202654j.
- Kumar, Atul; et al. (2011), "Functional ionic liquid mediated synthesis (FILMS) of dihydrothiophenes and tacrine", Green Chemistry 13: 2459, doi:10.1039/C1GC15410A.
- Kumar, Atul; et al. (2013), "Nanoparticle catalyzed reaction (NPCR): ZnO-NP catalyzed Ugi-reaction in aqueous medium", Green Chemistry 15: 2699, doi:10.1039/C3GC41101J.